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Meta-analysis is increasingly used in drug
development [1] and studies are often de-
signed with the consideration that a meta-
analysis could be performed [2]. Good meta-
analyses successfully combine information
from different studies to provide a better
understanding of the effect of a treatment [3];
however, there are examples of meta-analyses
that have generated controversial results [4,5].
The meta-analysis of Finasteride [3] in be-
nign prostatic hyperplasia (BPH) was based on
all randomized placebo-controlled trials that
were performed over a period of at least 12
months: three of the studies had been pub-
lished, one was reported as an abstract and
two were complete but unpublished. To avoid
selection bias, all placebo-controlled trials
were included. Furthermore, the authors had
access to individual patient data [6] from all
studies. In the comparison of Finasteride with
placebo among the six studies, the results re-
vealed heterogeneity that was related to prostate
volume. The effect of Finasteride was greater
in studies in which men averaged larger prostate
volumes, an effect that was not investigated
in the individual studies.
In the meta-analysis of all eight breast can-
cer screening trials [4,5], the published data
was studied and prespecified inclusion and
exclusion criteria were used. One of the con-
clusions reached was that there was no mor-
tality benefit associated with screening.
However, this deduction was based on only
two of the studies, which were deemed to
have no major defects in their design and ex-
ecution, and resulted in controversy [7–11].
The meta-analysis of breast cancer screening
trials proved more difficult because the study
protocols varied. 
In the meta-analysis of Finasteride, although
the entry criteria varied, a similar protocol
was used in each study. The two meta-analy-
ses started from the same point of using data
on all randomized studies. In one study, data
from all studies are included and a meta-re-
gression model is used to investigate hetero-
geneity; in the second study [4,5], studies are
included only if they satisfy the entry criterion.
Although there are strong reasons for omit-
ting studies in a meta-analysis that are con-
cerned with known bias, it is believed that it
is reasonable to start from the premise of
using as much data as possible.
This review highlights and evaluates the
methods that can be used to include studies
in a meta-analysis when: (i) data on the vari-
ability of the treatment effect cannot be ob-
tained from the study publication; and (ii) when
there is data available from non-randomized
studies. Such methods might be used in a
meta-analysis that incorporates published re-
ports. Methods used to deal with missing vari-
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Classical meta-analysis requires the same data from each clinical trial, thus
data-reporting must be of a high-quality. Imputation methods are used
to include studies that provide incomplete information on variability and
the fixed and random effects of a drug. Regression models can be used
to include studies other than randomized placebo-controlled studies. In
the example outlined here, the use of non-randomized single-arm studies
and studies against comparator treatments has little influence on the
estimation of the treatment effect in comparison with placebo, an effect
that is based on the randomized placebo-controlled studies. The inclusion
of other studies serves to increase the precision of the effect of the treatment
compared with baseline. Although multiple imputation techniques enable
a larger number of studies to be included, which will typically increase
the precision of the estimated effect, a careful sensitivity analysis is also
required.
www.drugdiscoverytoday.com
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ability estimates in study publications are unnecessary
when individual patient data is available [6,12,13]. Data
are presented that illustrate the problems and then demon-
strate the use of multiple imputation methods to overcome
the lack of data on treatment effect variability and meta-
regression methods that are employed when data from
non-randomized studies can be accessed.
Missing study-level variability estimates
Meta-analysis of Permixon
A meta-analysis of all available clinical trial data was un-
dertaken to estimate the effects of Permixon [14], a drug
therapy for BPH. Data from all published trials involving
Permixon, where peak urinary flow (Qmax) was recorded,
were available. There were six randomized placebo-con-
trolled studies [15–20], and data from a further three ran-
domized clinical trials of Permixon against other drugs
were available. The largest study compared Permixon to
Finasteride [21]; other studies compared Permixon with
Alfuzosin [22] and with Prazosin [23]. Data from one large
open-label study of Permixon [24] were also included.
The raw data (Table 1) were extracted from published pa-
pers and technical reports. Data quality is not uniform and
some early studies publish mean values without standard
deviations (SDs). Most studies quote the mean for the base-
line and end of study without the SD of the difference.
This is a serious limitation and one which the CONSORT
guidelines [25] seek to address. Table 1 was constructed
using the techniques for obtaining SDs, such as using 
p-values, F- and t-statistics and calculations from his-
tograms [13,26]. A meta-analysis involves the calculation
of a weighted average of study estimates of treatment dif-
ference, where the weight is typically the inverse variance
of the study estimate. The estimates of treatment differ-
ence can be calculated from the trial publication (Table 1)
on the assumption that the same subjects contribute to
baseline and end of study, but it is the variance that must
be imputed.
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Table 1. Data on duration of study and peak urinary flow rate extracted from published papers and reports
Peak flow (ml s−1)
Study type Group Duration of
study (days)
Baseline End of study N Refs
Mean SD Mean SD
OL Permixon 90 11.74 8.82 14.67 15.93 592 [24]
Permixon 30 11.84 7.49 15.26 11.89 82 [15]RPC
Placebo 30 12.42 8.25 13.48 8.59 94
Permixon 30 10.70 10.24 16.10 16.75 46 [16]RPC
Placebo 30 10.08 10.24 10.58 13.12 39
Permixon 30 10.33 3.42 13.70 3.56 15 [17]RPC
Placebo 30 9.23 2.64 9.43 2.72 15
Permixon 58 12.90 NA 16.20 NA 14 [18]RPC
Placebo 69 11.20 NA 11.80 NA 13
Permixon 60 9.59 NA 13.72 NA 11 [19]RPC
Placebo 60 10.22 NA 12.18 NA 11
Permixon 84 6.15 NA 8.50 NA 33 [20]RPC
Placebo 84 6.30 NA 8.60 NA 37
Permixon 84 9.75 7.29 11.25 8.77 20 [23]RC
Prazosin 84 10.36 7.86 10.83 11.07 22
Permixon 180 10.62 2.78 13.30 6.72 467 [21]aRC
Finasteride 180 10.76 3.09 14.02 7.38 484
Permixon 21 10.40 2.70 13.20 4.20 31 [22]RC
Alfuzosin 21 9.20 2.70 13.90 7.90 32
a
In the study performed by Carraro et al. [21], changes in the mean of 2.68 ml s−1 (SD of 6.36) and 3.26 ml s−1 (SD of 6.84) were reported for Permixon
and Finasteride, respectively. Imputed SDs were 6.32 and 11.19 ml s−1.
Abbreviations: N, number of subjects for which data is available; NA, not available; OL, open-label observational studies with no randomization;
RC, randomized studies with comparator drug therapies; RPC, randomized placebo-controlled studies; SD, standard deviation.
If the criteria of only using studies that publish appro-
priate data are adopted, which are normally taken to be an
estimated effect and its standard error (SE), then only one
study [21] (not one comparing Permixon with placebo) can
be used, which is the largest and most recent randomized
study. Thus, data from eight out of nine randomized stud-
ies are discarded, which clearly represents a huge loss of
information. In terms of patients, this study represents 954
out of 1499 patients in randomized studies. In terms of
understanding heterogeneity, it is the number of studies
included that is more important than the number of 
patients [27].
Statistical issues
The effect for treatment group k in study j is given by
Equation 1:
[Eqn 1]
where denotes the mean end of study value and
is the corresponding baseline mean. The SE can be calcu-
lated using Equation 2:
[Eqn 2]
where, is the end of study variance and the sample
size, with and the corresponding values at base-
line. To calculate the mean difference, each subject needs a
baseline and end of study value, therefore . The re-
peat observations for each individual imply that the base-
line and end of study values have a positive correlation
(denoted by ).
If the SDs and the correlation are known, then the SE of
the difference can be calculated and this forms the basis of
the imputation [26]; from the individual patient data for
one study [21], the correlations were calculated to be 0.34
for Permixon and 0.38 for Finasteride. For those studies
that published means and SDs at baseline and end of study
(seven studies), the effect was calculated as the difference
in the means and the SD was calculated using a common
value of 0.36 for the correlation. With more complete data,
it would be appropriate to check the validity of this 
approach and if necessary use different correlations.
For the three studies that published only mean values
and not SDs, the SDs at baseline and end of study were sep-
arately imputed from the weighted average of the SDs from
the other studies. At baseline this value can be calculated
from Equation 3:
[Eqn 3] 
If some of the studies are small, then could be
used in place of . Because there is little evidence to sug-
gest that the SD is dependent on treatment, we advocate
the pooling of treatment arms in the imputation of the SD.
Indeed, the pooled two-sample t-test, a common test of ef-
ficacy, assumes common SDs. If there is evidence of gross
differences in SDs over a treatment group, then it would
not be appropriate to pool the treatment arms and individ-
ual imputed SDs should be calculated.
The general strategy is one of using the available infor-
mation, that is, imputing values from the other studies
when information is unavailable. This is one of the unsat-
isfactory aspects of meta-analyses of published data. To in-
vestigate the consequences of these imputations, for the
example outlined here, sensitivity analyses and a multiple
imputation analysis were performed.
Fixed effect meta-analysis
An estimate of the treatment difference between Permixon
and placebo and the SE of this treatment difference are 
required from each study. The estimate of the treatment
difference is given by Equation 4 and the SE of the treat-
ment difference is calculated from Equation 5: 
[Eqn 4]
[Eqn 5]
The fixed effect estimate is a weighted average where the
weights are the inverse of the SEs (Equation 6 gives rise to
Equations 7 and 8) [13].
[Eqn 6]
[Eqn 7]
[Eqn 8]
The imputation method
Three randomized studies [15–17] for Permixon can be
used after imputation of the correlation between the base-
line and end of study values. Analysis of the data from
these three studies indicates that the effects of different
correlations are minimal on the estimated effect (Table 2).
The larger the correlation, the smaller the SE leading to a
smaller SE for the estimate.
To include the three randomized placebo-controlled
studies without SD information, it is necessary to perform
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additional imputation of the SDs at baseline and end of
study. The imputed SDs were calculated by pooling the
arms of all the studies (including the open-label and com-
parative studies) with SDs at baseline and end of study to
give imputed SDs of 6.32 ml s−1 and 11.19 ml s−1 for the
baseline and end of study, respectively; the two values are
derived from data from seven studies comprising 13 treat-
ment arms and 1939 patients. To give a more precise 
estimate [26], all studies were included in the analysis.
However, there is an argument for including only the 
randomized placebo-controlled trials, in this scenario the
estimates would have been 8.33 ml s−1 and 11.49 ml s−1 for
the baseline and end of study, respectively. Two of the
three studies that did not provide SDs were small, compris-
ing only 22 and 27 patients, and the treatment difference
is smaller than in the three randomized studies with SD
information. Consequently, direct comparison of the esti-
mates obtained for all six studies with a variable correla-
tion (Table 2) with the estimates obtained for the three ran-
domized trials shows a lower estimate, 2.6 ml s−1 compared
with 3.0 ml s−1. The SEs are smaller for the six studies be-
cause more studies, and consequently more patients, are
included. Changing the correlation primarily influences
the SE.
To investigate the sensitivity of the estimates to the base-
line and end of study SDs, the correlation is maintained at
a fixed value; all six randomized studies were used. Here, the
SDs vary from the minimum observed to the maximum. The
end of study SD is larger, more variable from study to study
and has a greater influence on the meta-analysis estimate
compared with the baseline value, which has little effect.
After imputation, the overall effect of Permixon is to in-
crease peak flow by 2.65 ml s−1 (SE of 0.86 ml s−1) compared
with placebo. This SE does not take into account uncer-
tainty that is associated with the imputation of the un-
known values. However, multiple imputation is used to
overcome this issue. Values for the missing SDs and corre-
lations are repeatedly imputed from probability distribu-
tions. The baseline and end of study variances are sampled
from gamma distributions that have the same expected
value and variance as the observed baseline and end of
study variances. The imputed SDs are the square roots of
these values. The correlations are sampled from a normal
distribution with mean 0.36 and SD 0.07, which was cho-
sen to ensure that ~95% of correlations would lie between
0.22 and 0.50.
Multiple imputation is repeated 500 times and the mean
is 2.649 ml s−1, with a mean for the SEs of 0.860 ml s−1,
which correspond to the original estimates. The variability
in the estimates is the variability that is induced by the im-
putation. The SD of these 500 estimates is 0.0577. This is
added to the original SE to take into account the imputa-
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Table 2. Effects of imputation on the randomized placebo-controlled studies
Study Baseline SD
(ml s-1)
End of study
SD (ml s-1)
Correlation Estimate Standard
error
Lower
95% CI
Upper 95% CI
NA NA 0.20 3.04 1.07 0.94 5.13
NA NA 0.36 3.04 0.96 1.16 4.92
Three studies with
SD information
NA NA 0.50 3.04 0.85 1.37 4.71
6.32 11.19 0.20 2.64 0.96 0.77 4.52
6.32 11.19 0.36 2.65 0.86 0.96 4.34
Six studies with
variable correlation
6.32 11.19 0.50 2.67 0.77 1.16 4.17
2.64 2.72 0.36 1.55 0.48 0.60 2.49
2.64 11.19 0.36 2.64 0.86 0.96 4.33
2.64 16.75 0.36 2.84 0.91 1.06 4.63
6.32 2.72 0.36 2.16 0.72 0.75 3.57
6.32 11.19 0.36 2.65 0.86 0.96 4.34
6.32 16.75 0.36 2.84 0.91 1.05 4.62
10.24 2.72 0.36 2.58 0.84 0.93 4.23
10.24 11.19 0.36 2.73 0.88 1.00 4.45
Six studies with
fixed correlation
10.24 16.75 0.36 2.85 0.91 1.06 4.64
The columns detailing values for end of study, correlation and estimate give the values used in the imputation process.
The columns detailing values for estimate, standard error and lower and upper 95% CI give the estimated treatment difference between Permixon and placebo.
For the three studies for which SDs were available, there is no imputation of SDs.
Abbreviations: CI, confidence interval; NA, not applicable; SD, standard deviation.
tion. This gives a value for the SE of 0.862 (calculated as
shown in Equation 9). 
[Eqn 9]
There is a small increase in the SE because the overall es-
timate is not sensitive to different imputed values (Table 2).
This is a typical occurrence because important information
about the SE of the treatment difference is contained in the
known sample sizes.
The heterogeneity statistic takes a value of Q = 1.73 on
five degrees of freedom and there is no need for random
effects. Typically, a random effects estimate would be used
and the multiple imputation procedure can easily be adapted.
Inclusion of studies other than randomized placebo-
controlled studies
Classical meta-analysis is based on the analysis of random-
ized trials only. There is merit in including non-random-
ized single-arm studies and studies in which the active
treatment is compared with a comparative treatment rather
than placebo. This gives no advantage for the estimation
of the difference between Permixon and placebo. However,
there is a benefit to the estimation of the effect of Permixon
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Each arm of all the studies is summarized by the effect and
its standard error (SE). The meta-analysis model is given by
Equation i:
[Eqn i]
where µ represents the overall mean effect (this is the aver-
age change in the Permixon group), τk is the effect of treat-
ment k relative to Permixon, uj represents the random ef-
fect of study j and εjk represents the sampling variability of
the effect, which is assumed to be known and equal to s2jk.
This is a multilevel or hierarchical model [36] and the es-
timates were obtained using the MLwiN software (Centre
for Multilevel Modelling; http://multilevel.ioe.ac.uk) [37].
Initially, a random effects model was used because it was
anticipated that the inclusion of more studies would give
rise to a greater heterogeneity. The first level is given by
Equation ii and the second level is represented by Equation iii:
[Eqn ii]
[Eqn iii]
The second level model can be extended to take into
account study variables that might influence the average
study effect in a systematic way. Such variables include the
length of the study, dummy variables for the individual studies
and study type; this extension gives Equation iv:
[Eqn iv]
where β measures the effect of the study level covariate cj
on the study effect, µj.
The first level of the model could also include covariates
that might explain imbalance in the treatment arms. In this
analysis, we permitted the treatment effects µ and τk to vary
randomly over the studies (Equation v).
[Eqn v]
However, no study level variation was observed. This
meta-regression model is one approach for investigating 
heterogeneity [29,38,39].
In the analysis of randomized placebo-controlled studies
with dummy variables representing the studies for compar-
ison with the imputation method analysis, the model fitted
is given by Equations vi and vii:
[Eqn vi]
[Eqn vii]
where µ represents the effect of Permixon in the reference
study, δj is the fixed effect of study j and τj1 is the random
treatment difference effect. 
Apart from a random effect, this is identical to the fixed
effect model used when illustrating the variance imputa-
tions. In the analysis of randomized placebo-controlled
studies excluding study dummy variables (based on random-
ized studies only), the model fitted is given by Equations viii
and ix:
[Eqn viii]
[Eqn ix]
where µ represents the effect of Permixon and τj1 is the 
random treatment difference effect. 
In the randomized placebo-controlled model with dummy
variables, the estimated treatment difference is a pooled
within-study estimate. This is not the case in this model,
where it is a difference of effects averaged over studies.
The model fitted in analysis of all studies with terms 
for different study types and comparative drugs is given by
Equations x and xi:
[Eqn x]
[Eqn xi]
where µ represents the effect of Permixon, τjk the treatment
effect where k = 1 corresponds to the comparison of
placebo with Permixon and k >1 corresponds to the other
drugs, ρj1 represents the effect of the other study types rela-
tive to randomized placebo-controlled trials and l indexes
the type of study.
The model used for the analysis of all studies that ignore
differences among study types is given by Equations xii and
xiii:
[Eqn xii]
[Eqn xiii]
Box 1. Statistical model
862000577086000 22 ... =+
jkjkjk ux ε ++τ +µ =
jkkjjkx ε +τ +µ =
j u+µ =µ oj
ojjj uc +β +µ =µ 
j1kkj u+τ =τ 
jk1jjjkx ε +τ +δ +µ =
j1 1j u+τ=τ 
jk1jjkx ε +τ +µ =
j11j u+τ =τ 
jk1jjkjklx ε +ρ +τ +µ =
j11j u+τ =τ 
jkjkjkx ε +τ +µ =
j11j u+τ =τ 
from baseline to end of study. Such
studies can be included within a sta-
tistical model [28–31] (Box 1).
Results
Although patients on placebo have a
slight increase in mean Qmax, the 95%
confidence interval (CI) contains zero
(i.e. no effect) in all studies (Figure 1).
Patients receiving Permixon display a
clear increase in peak flow and only in
four small studies does the 95% CI
contain zero.
Estimates from the meta-regression
models with covariates representing
the different study types are presented
in Table 3. Four analyses are presented:
(i) randomized placebo-controlled stud-
ies with dummy variables representing
the studies for comparison with the
imputation method analysis; (ii) ran-
domized placebo-controlled studies ex-
cluding study dummy variables; (iii) all
studies with terms for different study
types and comparative drugs; and (iv)
all studies but ignoring differences
among study types. There was no evidence of significant
heterogeneity and in all models the variance of the ran-
dom effect was estimated as zero.
The parameter estimate for placebo gives the estimated
change in the mean Qmax from baseline to end of study in
the placebo arm compared with the Permixon arm; this is
the treatment difference effect. It has a negative value 
because the increase in Qmax on placebo is less than the in-
crease on Permixon. The parameter estimate for Permixon
gives the change in Qmax from baseline to end of study for
Permixon. Analysis of the randomized placebo-controlled
study with dummy variables gives exactly the same esti-
mated treatment difference of 2.65 (SE of 0.86) ml s−1 as
the fixed effect analysis. Removing the dummy variables,
yields a mean increase on Permixon of 2.70 (SE of 0.86) ml
s−1 compared with placebo. The difference from the study
that incorporated the dummy variables is a result of the
later model no longer yielding a pure within-study esti-
mate. The estimated total increase in peak urinary flow
using Permixon from randomized placebo-controlled stud-
ies is 3.44 ml s−1.
In the model that accounts for different study types and
comparative drugs, the Permixon effect corresponds to 
the randomized studies only and the placebo estimate is
the treatment difference, which is also only present in 
randomized studies; identical values to the model of ran-
domized placebo-controlled studies that exclude dummy
variables are obtained. The terms for open and compara-
tive studies give the difference between the effect of
Permixon in these studies compared with the randomized
trials. The differences in effect between the open and com-
parative studies and the randomized study are negative, in-
dicating that the change in Qmax from baseline is less in
these studies compared with the randomized placebo-con-
trolled studies. However, the SEs in these cases are large,
which indicates that there is no significant difference. We
conclude that Permixon has the same general effect on
Qmax in all studies and therefore exclude the terms that rep-
resent differences among the study types. This gives an 
increase in Qmax associated with Permixon of 2.81 (SE of
0.23) ml s−1. The SEs are now significantly smaller because
more studies, including a large open-label study, have been
used to estimate the effect of Permixon. The estimated
treatment difference is now 2.06 (SE of 0.59) ml s−1.
Although this has a smaller SE than in the model of a ran-
domized placebo-controlled trial that includes dummy
variables, it is no longer a pure within-study estimate be-
cause it compares the average of the placebo arms with the
average of the Permixon arms. It is easy to include other
study level variables and the estimated effect of the use of
929
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Figure 1. Changes in mean peak urinary flow by study and treatment group. The size of
the points is proportional to the square root of the number of subjects. The summaries for
the Permixon and placebo arms of the studies are plotted with open circles. The
horizontal lines indicate the 95% confidence intervals.
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Permixon for one month is to reduce peak urinary flow by
0.086 (SE of 0.110) ml s−1.
Discussion
Treatment with Permixon is associated with an increase in
peak urinary flow of approximately 2.0 to 2.5 ml s−1. Over
the sensitivity ranges considered here, there was not a sub-
stantial change to the overall estimate. Imputation has a
greater affect on the precision of the estimate. There is no
imputation of the primary response from each study, only
imputation of the variability.
The inclusion of non-randomized single-arm studies and
the use of data from randomized studies that are not
placebo-controlled [32] have an effect on the estimated
treatment difference, but, in the example used, this effect
is only slight. Using only the randomized placebo-controlled
studies gives an estimate of treatment difference that is an
average of within-study comparisons. However, the inclu-
sion of other single-arm studies signifies that the treatment
difference is no longer completely a within-study compari-
son. A marked difference between the estimate from all the
studies and the estimates from the randomized studies im-
plies considerable heterogeneity and it is unwise to include
the non-placebo-controlled studies. If there are no large
discrepancies between the estimates, then the estimate
based on all studies is preferable because there is a wider
range of applicability and the precision will be smaller.
It is important to perform a full sensitivity analysis. In
the example used in this review, similar estimates were 
obtained, which implies that the results are not sensitive
to the studies included in the analysis. The precisions are
sensitive to the studies included and the inclusion of large
single-arm studies will increase the precision of the effect
of the treatment from baseline to end of study. The issues
here are similar to those involved in synthesizing infor-
mation, and similar statistical methods are used [33].
If the CONSORT guidelines for reporting clinical trials
are followed, then there should be no need for the imputa-
tion methods outlined in this review. Although these
guidelines, and the corresponding procedures for meta-
analysis [34], should improve meta-analyses in the future,
imputation could still be essential when using studies 
already published. In terms of the methodology used and
the reporting of procedures, earlier trials might not com-
pare as favourably with later trials. However, this is a 
feature of the evolving nature of clinical studies.
Imputation of the correlation between the baseline and
end of study measurements is another problem. In publi-
cations, there is limited information for the estimation of
this correlation and access to individual patient data is 
required. This is most likely to happen when the meta-
analysis of all clinical trials of a drug are carried out by a
statistician who is working for the company producing the
drug. The correlation affects the significance of the results.
If the correlation coefficient is equal to zero, then all the
estimated effects in this review are too precise. The larger
the correlation, the more precise the individual study ef-
fects and the greater the heterogeneity in effects observed
throughout the studies. In the absence of reliable infor-
mation, it is better to err on the side of using a low positive
930
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Table 3. Parameter estimates
Randomized placebo-
controlleda
Randomized placebo-
controlled ignoring
study differences
All study type with
terms for different study
types
All studies ignoring
study type differences
Estimate SE Estimate SE Estimate SE Estimate SE
Permixon 3.60 0.95 3.44 0.67 3.44 0.67 2.81 0.23
Placebo -2.65 0.86 -2.70 0.86 -2.70 0.86 -2.06 0.59
Open - - - - -0.51 0.91 - -
Comparative - - - - -0.76 0.72 - -
Prazosin - - - - -2.21 2.37 -2.34 2.36
Finasteride - - - - 0.58 0.41 0.46 0.39
Alfuzosin - - - - 2.02 1.33 1.90 1.32
aEstimates for individual studies were (SE are given in parentheses and Descotes et al. [15] was used as the reference study): Champault et al. [16], estimate of
0.56 (1.78); Emili et al. [17], estimate of −0.56 (1.00); Tasca et al. [18], estimate of −0.33 (2.20); Boccafoschi et al. [19], estimate of 0.77 ( 2.41); and
Reece-Smith et al. [20], estimate of 0.12 (1.50).
Abbreviation: SE, standard error.
correlation because this will lead to conservative conclu-
sions (wider CIs).
Although there was little numerical effect in the Permixon
example used here, multiple imputation is a useful tool for
correcting variability estimates. By comparison with the
available data on the sample sizes and baseline and end of
study means, there is only a small amount of missing
information that needs to be imputed to calculate the SEs.
The greatest benefit comes from the initial performance of
the imputation because this process increases the number
of studies that can be included. The example here is ex-
treme because no single randomized placebo-controlled
study provided the SE of the treatment difference. Without
imputation, no meta-analysis could be attempted. The mul-
tiple imputation model is similar to Bayesian models [35].
This leads to the issue of whether or not the pooling of
data should be attempted if some SEs are missing. Surely
missing variability estimates mean poor studies and so
only a qualitative summary should be carried out. We be-
lieve that omitting studies without SE information is anal-
ogous to missing out unpublished studies – a bias could
arise. Imputation is a means of including more studies and
provides a method for performing a sensitivity analysis of
studies providing complete information. We do not advocate
an uncritical use of this technique, but suggest it as a strat-
egy for widening the range of applicability of the analysis.
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